The deal will involve a combined 350-strong portfolio of non-branded products that US generics firm Mylan will manufacture and develop, before handing over to Pfizer for commercialisation and marketing. The companies will continue to operate independently in Japan, but will share costs and profits.
The agreement is in keeping with the strategy Pfizer employs in key generic drug markets Indian and Brazil where it has manufacturing partnerships with Strides Acrolabs and Laboratorio Teuto Brasileiro.
Pfizer was not immediately available for comment when contacted by in-Pharmatechnologist.com.
Mylan operates in Japan through its Tokyo-based Mylan Seyaku subsidiary, which has a manufacturing unit in Kawagoe.
The firm also has an active pharmaceutical ingredient (API) production business – Hyderabad, India headquartered Mylan Laboratories Limited - which has nine drug active and intermediate manufacturing facilities located in India and China.